Invitae reported after the close of the market recently that its fourth quarter 2019 revenues increased 47 percent from the prior year.

Diagnostics manufacturer Quidel reported after the close of the market recently that its fourth quarter revenues rose 15 percent year over year, due primarily to growth in its rapid immunoassay business.

Foundation Medicine and Chugai Pharmaceutical said recently they have entered into an agreement with the National Cancer Center Japan to use Foundation's liquid biopsy test as part of an initiative targeting advanced cancer patients.

Bio-Rad Laboratories said after the close of the market recently that its fourth quarter revenues rose approximately 1 percent year over year.

Guided Therapeutics is kicking off 2020 with a renewed focus.

Abbott Laboratories has won a nod from FDA for a new alternative surgical technique for the HeartMate 3 Left Ventricular Assist Device (LVAD).

Personalized medicine is also advancing thanks to advances in in vitro diagnostics technology.

“Additive manufacturing has made its way into our healthcare system,” says Mark Wehde of Mayo Clinic Division of Engineering.

Wearable technologies could help address some of our greatest healthcare unmet needs, says Maria Shepherd of Medi-Vantage.

“2019 was really the year of connected care/digital health—and there’s so much more to come,” says Ralph Hugeneck, senior director of technology at Nypro a Jabil Company.

One of the biggest deals in diagnostics this year could be in the process of unfolding, according to a report from Bloomberg.

A common cardiac blood test done before surgery can predict who will experience adverse outcomes after most types of surgery, said researchers from Hamilton Health Sciences.

Irvine, California-based Genomic Testing Cooperative (GTC) said recently it is collaborating with C2i Genomics to develop liquid biopsy tests for solid tumor staging and monitoring.

Illumina and Genomics England announced recently a new agreement to sequence up to 300,000 genomes over five years.

Single Technologies recently announced it has raised SEK15 million ($1.6 million) to support further development of its next-generation sequencing platform.